Veru Announces FDA Approval Of ENTADFI, A New Treatment For Benign Prostatic Hyperplasia

–ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia–
 

–Commercialization Will Start Early Calendar Year 2022–

–ENTADFI to Be Marketed and Distributed by Veru's Direct to

—ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia–
 

–Commercialization Will Start Early Calendar Year 2022–

–ENTADFI to Be Marketed and Distributed by Veru's Direct to Patient Telemedicine and Telepharmacy Services Platform–

–Veru Partners with GoodRx, a National Healthcare Company that Operates a Telemedicine Platform that Connects Patients to Over 75,000 US Pharmacies–